| 摘要 |
The present disclosure provides pharmaceutical compositions comprising the atropisomers of 3-substituted-4-arylquinolin-2-one derivatives, as in fig 1, substituents of which are as defined in the specification, and methods for the treatment of conditions sensitive to potassium channel opening activity such as ischemia, stroke, convulsions, epilepsy, asthma, irritable bowel syndrome, migraine, traumatic brain injury, spinal cord injury, sexual dysfunction and urinary incontinence.
|
